Thursday, March 05, 2020 7:13:02 PM
My notes from an extraordinary meeting. We are going ahead (in spite of naysayers and shorts). Maybe I am missing a lot, but these are my mean takeaways:
BLA clinical has been finalized!!! (remember we have rolling application and this is the one that takes more time to study by FDA).
There will not be any dilutive financing. S0 we can rest easy with this one.
Financing is coming. Several possibilities (4 investors under evaluation). Most likely will be benign debt.
Coronavirus: one hour ago IND and protocol have been completed. Expected to file FDA tomorrow. Announcement on Monday with all details. Quest clinical in San Francisco ready to inject first patient New York Presbiterian Brooklyn Methodist want to enroll patients Stefano Rusconi Italy wan to enroll patients also.
Going full blast with Nash
Up-Listing a priority, however the cash in hand requirements ($100M NSE, $90M NASDAQ) are such that is better to wait until financing or deals are made.
Will present in conference American Association of cancer research
Commercial name: Virologics
Question about GILD: “GILD: I am hoping we don’t get an offer until we get a BTD designation. If somebody offers something and shareholders approve I am up for it.”
Dr. Patterson in Coronavirus: Of the 20 companies listed in article most are working on Vaccine or anti-viral. Only one (us) is ready with a good safety profile.
IND and protocol for MS in a couple of weeks.
March 29 meeting: Oncologist Pathologists, radiologists, open discussion and great opportunity to share ideas and come up with strategies.
BTD for MTNBC applied on January 10th updated data on Feb 6th. According to FDA guidelines 60 Days Will be up on 6 days or so unless they choose to reset the date.
New BTD we have IND, Lazeai have received. Have 2 patinet with different cancers and another one we could file based in mechanism of action. Lab doctor called several times and say that he had never seen such results so definitely there are responders.
TFDA for Cancer, HIV and Coronavirus” Already signed letter of intent an NDA 30 days started already. AMAREX was the venue. They shared data with their branch in Taiwan so it will be expedited for BTD for cancer and for HIV. They want to see some paints from that region.
CFDA document already transferred. They already transmitted them to CFDA so is in progress.
Longen: 9 days from today Letter of Intent will lapse. Working hard on final term sheet. Will inform what happens and if it happens.
Licensing with another very solid company with financial background (Taiwan) will be announcing something shorty. Both companies want to buy 24K plus 600K vials of commercial grade Leronlimab for Coronavirus and Oncology. Might get to the point that we are short of vials.
Update in patients:
7 Injected Yesterday 3/4/2020
8 Will be Injected Friday 3/6/2020
9 Passed screening, injection date TBD
10 Passed screening, injection date TBD
11 Will be Phase1/2b in Houston site
12 Will be Phase 1/2b in Houston site
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM